Arecor and CPI Partner to Enhance Biologics' Compatibility with Containers - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Arecor and CPI Partner to Enhance Biologics' Compatibility with Containers


Arecor and the Center for Process Innovation (CPI) Biologics are working on a project to enhance the compatibility of biologics with their containers, and thereby, improve the stability and shelf-life of these medicines throughout transportation and storage. 

The components of vials and syringe can adversely affect the stability of some biologics, causing degradation and making them unsuitable for administration. The collaboration between Arecor and CPI Biologics seeks to address this issue by determining the actual causative components and understanding the degradation mechanisms. The goal is to develop an efficient screening system that can detect compatibility issues during the development of novel biologics. The tool kit will enable the determination of formulation and container selection strategies that will counteract these effects and ensure the stability of biologics in both standard and state-of-the-art delivery devices.

The project starts with a proof-of-concept phase over a six-month period, and if successful, it could potentially transition into a development phase to establish standardized procedures and tools for the biopharmaceutical industry.

This is the first industry partnership that CPI Biologics has undertaken in association with its £38m National Biologics Manufacturing Center (NBMC) and will be performed at CPI’s Wilton laboratories and clean rooms in advance of the opening of the NBMC in 2015.

Source: Arecor

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here